Lu sur http://www.ncbi.nlm.nih.gov/pubmed/27358333
Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum
1. Neurology. 2016 Jun 29. pii: 10.1212/WNL.0000000000002790. [Epub ahead of print]
International consensus guidance for management of myasthenia gravis: Executive
Sanders DB(1), Wolfe GI(2), Benatar M(2), Evoli A(2), Gilhus NE(2), Illa I(2),
Kuntz N(2), Massey JM(2), Melms A(2), Murai H(2), Nicolle M(2), Palace J(2),
Richman DP(2), Verschuuren J(2), Narayanaswami P(2).
© 2016 American Academy of Neurology.
To develop formal consensus-based guidance for the management of myasthenia gravis (MG).
In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international experts was convened.
The RAND/UCLA appropriateness methodology was used to develop consensus guidance statements. Definitions were developed for goals of treatment, minimal manifestations, remission, ocular MG, impending crisis, crisis, and refractory MG.
An in-person panel meeting then determined 7 treatment topics to be addressed. Initial guidance statements were developed from literature summaries.
Three rounds of anonymous e-mail votes were used to attain consensus on guidance statements modified on the basis of panel input.
Guidance statements were developed for symptomatic and immunosuppressive treatments, IV immunoglobulin and plasma exchange, management of impending and manifest myasthenic crisis, thymectomy, juvenile MG, MG associated with antibodies to muscle-specific tyrosine kinase, and MG in pregnancy.
This is an international formal consensus of MG experts intended to be a guide for clinicians caring for patients with MG worldwide.
PMID: 27358333 [PubMed - as supplied by publisher]